CL2021003273A1 - Composición farmacéutica parenteral del agonista dual glp1/2 - Google Patents

Composición farmacéutica parenteral del agonista dual glp1/2

Info

Publication number
CL2021003273A1
CL2021003273A1 CL2021003273A CL2021003273A CL2021003273A1 CL 2021003273 A1 CL2021003273 A1 CL 2021003273A1 CL 2021003273 A CL2021003273 A CL 2021003273A CL 2021003273 A CL2021003273 A CL 2021003273A CL 2021003273 A1 CL2021003273 A1 CL 2021003273A1
Authority
CL
Chile
Prior art keywords
agonist
pharmaceutical composition
parenteral pharmaceutical
dual glp1
glp1
Prior art date
Application number
CL2021003273A
Other languages
English (en)
Inventor
Lise Giehm
Alistair Vincent Gordon Edwards
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of CL2021003273A1 publication Critical patent/CL2021003273A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas adecuadas para su administración parenteral a sujetos humanos. Específicamente, la presente invención se relaciona con composiciones farmacéuticas isotónicas de administración parenteral.
CL2021003273A 2019-06-14 2021-12-09 Composición farmacéutica parenteral del agonista dual glp1/2 CL2021003273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19180233 2019-06-14

Publications (1)

Publication Number Publication Date
CL2021003273A1 true CL2021003273A1 (es) 2022-07-22

Family

ID=66867001

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003273A CL2021003273A1 (es) 2019-06-14 2021-12-09 Composición farmacéutica parenteral del agonista dual glp1/2
CL2021003272A CL2021003272A1 (es) 2019-06-14 2021-12-09 Composición farmacéutica parenteral del agonista dual glp1/2

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021003272A CL2021003272A1 (es) 2019-06-14 2021-12-09 Composición farmacéutica parenteral del agonista dual glp1/2

Country Status (14)

Country Link
US (2) US20230212227A1 (es)
EP (2) EP3982920A1 (es)
JP (2) JP2022535555A (es)
KR (2) KR20220020819A (es)
CN (2) CN113966225A (es)
AU (2) AU2020290014B2 (es)
BR (2) BR112021020941A2 (es)
CA (2) CA3138716A1 (es)
CL (2) CL2021003273A1 (es)
IL (2) IL286990A (es)
MX (2) MX2021015153A (es)
SG (2) SG11202111312UA (es)
WO (2) WO2020249782A1 (es)
ZA (1) ZA202107825B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175410A1 (en) 2021-02-18 2022-08-25 Zealand Pharma A/S Composition for treating short bowel syndrome
KR20240058121A (ko) 2021-09-03 2024-05-03 질랜드 파마 에이/에스 투여 용법
CN116655772A (zh) * 2022-02-18 2023-08-29 成都奥达生物科技有限公司 一种长效的glp-1/glp-2双激动剂化合物
EP4323413A1 (en) * 2022-03-30 2024-02-21 Beijing QL Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
WO2024061919A1 (en) * 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239364T3 (es) 1996-09-09 2005-09-16 Zealand Pharma A/S Sintesis de peptidos en fase solida.
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
CN105849122B (zh) * 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
EP3212217A1 (en) 2014-10-31 2017-09-06 Gubra ApS Compositions and peptides having dual glp-1r and glp-2r agonist activity
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
PE20191083A1 (es) 2016-12-09 2019-08-20 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2

Also Published As

Publication number Publication date
CN113966226A (zh) 2022-01-21
WO2020249778A1 (en) 2020-12-17
AU2020293576A1 (en) 2021-11-04
JP2022535555A (ja) 2022-08-09
CN113966225A (zh) 2022-01-21
CA3138716A1 (en) 2020-12-17
MX2021015153A (es) 2022-01-18
US20230212227A1 (en) 2023-07-06
EP3982919A1 (en) 2022-04-20
ZA202107825B (en) 2024-02-28
KR20220020821A (ko) 2022-02-21
EP3982920A1 (en) 2022-04-20
BR112021024651A2 (pt) 2022-01-04
AU2020290014B2 (en) 2022-10-27
CA3138715A1 (en) 2020-12-17
AU2020290014A1 (en) 2021-11-04
JP2022535556A (ja) 2022-08-09
BR112021020941A2 (pt) 2021-12-21
SG11202111312UA (en) 2021-12-30
US20220202704A1 (en) 2022-06-30
MX2021015154A (es) 2022-01-18
SG11202111311WA (en) 2021-12-30
IL286990A (en) 2021-12-01
KR20220020819A (ko) 2022-02-21
WO2020249782A1 (en) 2020-12-17
IL286991A (en) 2021-12-01
CL2021003272A1 (es) 2022-07-22

Similar Documents

Publication Publication Date Title
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
PH12017502052A1 (en) Substituted tetrahydroquinolinone compounds as ror gamma modulators
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CY1120089T1 (el) Παραγωγα ουριας ή φαρμακολογικως αποδεκτα αλατα εξ' αυτων χρησιμα ως αγωνιστες του παρομοιου με υποδοχεα πεπτιδιου φορμυλιου 1(fprl-1)
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CL2021002331A1 (es) Formulaciones de anticuerpo anti-il-36r
CR20190208A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
PA8805801A1 (es) Agonistas novedosos de los receptores de glucorticoides
CO2017006174A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
AU2018274765A1 (en) Formulations for treatment of post-traumatic stress disorder
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
CL2020003034A1 (es) Agonistas de tlr7
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
CL2022001970A1 (es) Conjugados de proteínas-compuestos antivirales
AR106981A1 (es) Una composición antimicrobiana
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
BR112017023264A2 (pt) composição
EA201992883A1 (ru) АНТИТЕЛА К TrkB
BR112018075817A2 (pt) composto de fórmula (i), medicamento e composição farmacêutica
BR112019022918A2 (pt) Agentes farmacêuticos, composições e métodos relativos aos mesmos